Using SGLT2 inhibitors to treat lupus nephritis in patients with chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy of dapagliflozin, an SGLT2 inhibitor, in patients with lupus nephritis and chronic kidney disease. The study focuses on patients with biopsy-proven lupus nephritis who are experiencing stable disease and are on standard maintenance therapy. By evaluating the impact of dapagliflozin on renal outcomes, the trial aims to provide a novel therapeutic approach for managing chronic kidney disease in this patient population. The study will assess changes in kidney function and other health outcomes over the course of treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with biopsy-proven Class III or IV or V LN according to the ISN/RPS 2003 classification
2. Patients with CKD (eGFR 15-60mL/min)
3. Patients in quiescent disease (defined as SLEDAI score \<4 with no points in the renal domain)
4. Patients on a stable dose of prednisolone (PRED 5-7.5 mg/D) alone or in combination with MMF (\<=1.5 g/D) or AZA (\<=150 mg/D) in the past 3 months

Exclusion Criteria:

1. Patients with biopsy-proven glomerulonephritis other than LN or hereditary kidney diseases
2. Patients with type 1 diabetes mellitus (DM)
3. Patients with stage 5 CKD or ESKD on renal replacement therapy
4. Patients with frequent urinary tract infections
5. Patients with history of ketoacidosis

Where it's running

• Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Desmond Yap, MD (HK) — The University of Hong Kong
• Study coordinator: Desmond Yap, MD (HK)
• Email: desmondy@hku.hk
• Phone: 85222554385

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• Triple therapy with voclosporin, MMF and prednisolone in lupus nephritis

  This trial tests whether adding voclosporin to standard lupus nephritis treatment (MMF and prednisolone) early on improves kidney inflammation compared to standard therapy alone.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07760480

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

• Impact of TAVR on kidney function in people with aortic valve disease

  This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT07626710

• LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis

  This trial tests whether adding LUPKYNIS to other biologics (belimumab, obinutuzumab, or anifrolumab) plus a mycophenolic acid analog and a steroid can rapidly improve kidney health in adults with biopsy-proven lupus nephritis.

  Recruiting at 27 sites Phase 4 Aurinia Pharmaceuticals Inc. · La Mesa, California and 26 other locations · NCT07611214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.